乳鐵蛋白 Lactoferrin × 免疫功能
The evidence for lactoferrin in immune function is population-dependent and dominated by a contradiction between small positive trials and the single best-powered hard-endpoint trial.
The evidence for lactoferrin in immune function is population-dependent and dominated by a contradiction between small positive trials and the single best-powered hard-endpoint trial. The largest and best-designed RCT, ELFIN (PMID 30635141, n=2203, UK NIHR-funded), was NULL for late-onset sepsis in very preterm infants (adjusted RR 0.95, 95% CI 0.86-1.04, p=0.233), directly contradicting the earlier smaller Manzoni LISA trial (n=472, RR 0.34) which had reported a large benefit. Meta-analyses are split by age: the 2022 systematic review (PMID 35481594, 25 studies) showed RTI reduction in infants and children (OR 0.78) but no effect in adults (OR 1.00); a single small preschool RCT (PMID 38397361, n=50) reported a 50% episode reduction but is too small and single-centre to be confirmatory. No major authority endorses lactoferrin for immune function: WHO does not address it; CDC, NHS, Mayo Clinic, Cleveland Clinic and Harvard Health publish no recommendation; the American Academy of Pediatrics has not endorsed routine preterm-infant supplementation post-ELFIN; NIH ODS has no dedicated fact sheet; EFSA has authorised bovine lactoferrin only as a safe novel food, with no Article 13/14 health claim. Regulatory acceptance is purely as a food ingredient (FDA GRAS, EU novel food, TFDA additive 「08112」), not as an evidence-based immune therapy. A B grade would overstate a body of evidence whose largest hard-endpoint trial is null and whose adult RTI signal is null; C (limited, mixed, population-dependent, no society endorsement) is the honest grade. Lactoferrin is also absent from the Examine database entirely, so there is no aggregator-level grade to reconcile with.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群（以 PTT BabyMother 板為主）對乳鐵蛋白提升免疫力的討論集中在嬰幼兒族群，整體反應分歧：少數家長覺得換季或生病頻率有減少、症狀較輕，但多數鄉民認為效果難以證明，常歸因於小孩離開托嬰環境、病毒適應或睡眠飲食改善，普遍以「吃心安」形容。社群強調均衡飲食、曬太陽、充足睡眠比補單一營養品重要，購買前建議諮詢醫師。
分歧（無共識）：少數家長反映生病頻率下降、症狀較輕，但多數認為效果難以證明、多為心安，常被歸因於托嬰環境改變或病毒適應而非乳鐵蛋白本身。
- 便秘（多人提及）
- 家長擔憂過量蛋白類補充與性早熟（軼事性，未經證實）
- 腎結石風險（提問者關切，未經證實）
依論壇被提及頻率，非銷售或品質排序。
- 優兒康
- 卡蘿琳
- 孕哺兒
- Encs 初乳蛋白
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 充足且規律的睡眠
- 疫苗接種
- 規律身體活動
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-immune-function-INT-lactoferrin-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "乳鐵蛋白能改善免疫功能",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}